Welcome to our dedicated page for Corbus Pharmaceu SEC filings (Ticker: CRBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing the science-heavy disclosures of a clinical-stage biotech like Corbus Pharmaceuticals can feel daunting. Phase 1/2 trial data, licensing clauses and dilution risks sprawl across hundreds of pages, while critical Corbus Pharmaceuticals insider trading Form 4 transactions are filed at unpredictable hours.
Stock Titan solves that problem. Our platform delivers Corbus Pharmaceuticals SEC filings explained simply with AI-powered highlights that turn technical jargon into plain language. Whether you need the latest Corbus Pharmaceuticals quarterly earnings report 10-Q filing, an alert the moment a director files a Corbus Pharmaceuticals Form 4 insider transactions real-time, or want the Corbus Pharmaceuticals 8-K material events explained, we’ve got it covered. Our algorithms surface pipeline milestones for CRB-701 and CRB-601, flag funding runway notes hidden in MD&A, and create side-by-side comparisons so the Corbus Pharmaceuticals annual report 10-K simplified becomes actionable, not overwhelming.
Use cases are clear: monitor Corbus Pharmaceuticals executive stock transactions Form 4 before pivotal trial readouts, benchmark R&D spend through our Corbus Pharmaceuticals earnings report filing analysis, or review the Corbus Pharmaceuticals proxy statement executive compensation to see how management incentives align with shareholder value. From pipeline progress tables to liquidity footnotes, understanding Corbus Pharmaceuticals SEC documents with AI means informed decisions without sifting through every exhibit. Real-time updates, concise summaries, complete coverage—everything you need from idea to trade.
The Vanguard Group filed Amendment No. 2 to Schedule 13G for Daily Journal Corp. (DJCO). As of the event date 06/30/2025, Vanguard reports beneficial ownership of 100,243 DJCO common shares, equal to 7.27 % of the outstanding class.
Voting power is minimal: 0 shares sole and 1,373 shares shared. Dispositive power is larger, with 97,833 shares sole and 2,410 shares shared. Vanguard files under Rule 13d-1(b) in its capacity as an investment adviser ("IA"), indicating the position is held in the ordinary course of business without the intent to influence control. The certification is signed by Ashley Grim, Head of Global Fund Administration, on 07/29/2025.
The amendment confirms Vanguard remains a >5 % passive institutional holder, providing updated ownership details but no indication of strategic changes or control ambitions.
FAQ
What is the current stock price of Corbus Pharmaceu (CRBP)?
What is the market cap of Corbus Pharmaceu (CRBP)?
What is the core focus of Corbus Pharmaceuticals Holdings, Inc.?
What are the key product candidates in Corbus’s portfolio?
How does CRB-701 differentiate itself from conventional treatments?
What is the significance of using monoclonal antibody technology in Corbus’s approach?
How does Corbus Pharmaceuticals approach the treatment of obesity?
What are the advantages of Corbus's diversified portfolio?
How does Corbus ensure the rigor of its clinical development process?
In what ways does Corbus Pharmaceuticals differentiate itself in a competitive market?
